Exciting news from Ionis Pharmaceuticals! Potentially faster approval for HTTRx!

Ionis Pharmaceuticals.jpg

Ionis Pharmaceuticals, Inc. announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to IONIS-HTTRx for the treatment of people with Huntington's disease (HD). This PRIME designation means this potentially disease-modifying drug for people with Huntington's disease to regulatory approval faster. This is exciting news! Read the full press release.

Powerful new approach helps understand molecular alterations in neurological disease



Neurological diseases are typically associated with a multitude of molecular changes. But out of these thousands of changes in gene expression, which ones are actually driving the disease? Read full story.

Funding for this work was provided, in part, by a grant from the Hereditary Disease Foundation.

SAVE THE DATE - Jackie's Walk 4 HD, October 14, 2018

Jackie's Walk for HD 2018 will be held October 14th, at Glen Island Park in New Rochelle, NY with the Hereditary Disease Foundation (HDF). HDF was the first organization funding research and continues to inspire innovation in the field of Huntington's disease research. We are so happy to run this event as part of HDF’s 50th Anniversary celebration.

We hope that you will join us in this day of fun and celebration as the latest research for HD is so promising!

Click for more details.

Pope Francis champions Huntington's disease, by HDF President Nancy Wexler


"From the moment I first visited Venezuela in 1979, which has the world’s highest prevalence of Huntington’s disease, I was moved and motivated to help and improve the lives of patients with Huntington’s disease, their families and their communities." 

Read full letter.